Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
October 12, 2023 16:05 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
October 11, 2023 08:00 ET
|
Vir Biotechnology, Inc.
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
October 05, 2023 16:30 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
October 03, 2023 07:59 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
August 29, 2023 16:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the...
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
July 26, 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
June 29, 2023 09:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs...